NEW YORK (GenomeWeb News) – Affymetrix said today that it has extended its Collaborations in Cancer Research Program to North America and has signed alliances with 25 cancer researchers on the continent.
The new agreements expand the CCRP, which was launched a year ago and initially included collaborations with 15 researchers throughout Europe.
Affymetrix said the collaborators are using integrated genomics products from the firm including its SNP 6.0 array and Human Exon 1.0 ST array to research more than 10 types of cancer. The Santa Clara, Calif.-based microarray firm said that it expects initial data from the studies to be released in the next three to six months.
One of the researchers involved in the program, Tak Mak Wah, a professor in the department of medical biophysics at the University of Toronto, said that he is using the SNP 6.0 arrays to obtain a comprehensive profile of genetic abnormalities for discovering novel molecular targets. “The ability to integrate the exon and SNP array data will help us identify candidate driver genes underlying these genomic abnormalities and speed up their validation,” he said in a statement.
Affymetrix is partially funding selected research projects that demonstrate clinical utility, helping participants obtain tools and training, and providing forums where investigators can share knowledge and best practices.
In addition to Wah, the firm is collaborating with researchers from the University of Michigan, the Broad Institute, Memorial Sloan-Kettering Cancer Institute, and Oregon Health and Science University, among others.
Affymetrix expects to expand the CCRP to the Asia-Pacific region later this year.